0LEC.L AI Price Prediction

The negative EPS and PE ratio indicate that Cardlytics remains unprofitable, with losses significant enough to dominate the valuation metrics. At this stage, the equity story is still about turnaround and survival rather than earnings growth, which materially increases risk for shareholders.

• Negative EPS of -2.12 signals ongoing net losses and an absence of current earnings support for the share price.
• A PE ratio of -0.35 confirms that the stock is loss-making and being valued on expectations of future improvement rather than present profitability.
• Given the deep losses implied by EPS and PE, profitability ratios are likely weak, suggesting pressure on margins and a need for either substantial revenue growth or cost restructuring to reach breakeven.

The stock trading at $0.73 and down 16.5% over the last month reflects strong negative momentum and market skepticism. With price far below the 200-day moving average and an RSI near neutral, the trend is weak without clear signs of an imminent technical rebound.

• Current price of $0.73, with a 16.5% decline over the last month, indicates recent selling pressure and weak investor confidence.
• The 200-day moving average at $9.79 versus the current price highlights a massive long-term downtrend and suggests the stock is deeply underwater relative to its historical levels.
• RSI at 46.03 is near neutral, implying the stock is neither oversold nor overbought; this suggests the downtrend is more structural than purely technical and does not yet show a strong contrarian buy signal.

Overall, Cardlytics appears to be in a challenged position, with a deeply depressed share price, substantial historical drawdown versus its 200-day average, and ongoing losses. While alternative data show some underlying platform activity, they do not yet offset the financial and technical risks, leaving the risk-reward profile skewed to the downside in the near term.

• Persistent unprofitability and a very low share price relative to long-term averages point to elevated financial and execution risk.
• Alternative data suggest stabilization and cost discipline rather than clear growth acceleration, which is insufficient to counteract the currently negative stock trend and loss-making profile.